Literature DB >> 26663797

Galectin-3 Concentration in Liver Diseases.

Monika Gudowska1, Ewa Gruszewska1, Bogdan Cylwik2, Anatol Panasiuk3, Magdalena Rogalska3, Robert Flisiak3, Maciej Szmitkowski1, Lech Chrostek4.   

Abstract

The aim of this study was to evaluate the changes in serum galectin-3 concentration during liver diseases. The results were compared with hyaluronic acid concentration in combination with prothrombin index as a HAPRI index. Serum samples were obtained from 20 healthy volunteers and 109 patients suffering from alcoholic cirrhosis (AC)--57, non-alcoholic cirrhosis (NAC)--30 and toxic hepatitis (HT)--22 patients. Cirrhotic patients were classified according to Child-Pugh scale. Galectin-3 concentration was measured by the chemiluminescent microparticle immunoassay and HAPRI index was calculated using a formula. There was a significant increase in the serum concentration of galectin-3 in patients with AC, NAC and HT, and significant differences between diseases were observed. The mean galectin-3 concentration in AC was significantly higher than that in HT. The serum galectin-3 level differs significantly according to severity of cirrhosis and was the highest in Child-Pugh class C. The sensitivity, specificity, accuracy, positive and negative predictive values and the area under the ROC curve for galectin-3 and HAPRI were high and similar to each other. In conclusion, galectin-3 is a good marker of fibrosis in cirrhosis and toxic hepatitis, which reflects the stage of liver damage, like the HAPRI index.
© 2015 by the Association of Clinical Scientists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26663797

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  13 in total

1.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

2.  The effects of galectin-3 depletion apheresis on induced skin inflammation in a porcine model.

Authors:  Nalu Navarro-Alvarez; Beatriz Goncalves; Alec R Andrews; Zhaohui Wang; Zhirui Wang; Edward Harrington; Jigesh Shah; David H Sachs; Isaac Eliaz; Christene A Huang
Journal:  J Clin Apher       Date:  2018-03-23       Impact factor: 2.821

3.  Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

Authors:  Sabrina Krautbauer; Lisa Rein-Fischboeck; Elisabeth M Haberl; Rebekka Pohl; Reiner Wiest; Christa Buechler
Journal:  Clin Exp Med       Date:  2017-07-25       Impact factor: 3.984

Review 4.  Adipokines in Liver Cirrhosis.

Authors:  Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

5.  Clinical significance of galectin-3 expression in malformed hepatic venous tissue.

Authors:  Junbo Qiao; Yongwei Chen; Changxian Dong; Jin Li
Journal:  Indian J Med Res       Date:  2018-12       Impact factor: 2.375

6.  Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy.

Authors:  Thomas A Premeaux; Shireen Javandel; Kalei R J Hosaka; Meredith Greene; Nicholas Therrien; Isabel E Allen; Michael J Corley; Victor G Valcour; Lishomwa C Ndhlovu
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

7.  Intravenous Arginine Administration Benefits CD4+ T-Cell Homeostasis and Attenuates Liver Inflammation in Mice with Polymicrobial Sepsis.

Authors:  Chiu-Li Yeh; Sharon Angela Tanuseputero; Jin-Ming Wu; Yi-Ru Tseng; Po-Jen Yang; Po-Chu Lee; Sung-Ling Yeh; Ming-Tsan Lin
Journal:  Nutrients       Date:  2020-04-10       Impact factor: 5.717

8.  Liver Disease as a Predictor of New-Onset Atrial Fibrillation.

Authors:  William A Huang; Eric A Dunipace; Julie M Sorg; Marmar Vaseghi
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

Review 9.  Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner.

Authors:  Seok-Jun Kim; Kyung-Hee Chun
Journal:  BMB Rep       Date:  2020-04       Impact factor: 4.778

10.  Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model.

Authors:  Luis V Herrera-Marcos; Roberto Martínez-Beamonte; Manuel Macías-Herranz; Carmen Arnal; Cristina Barranquero; Juan J Puente-Lanzarote; Sonia Gascón; Tania Herrero-Continente; Gonzalo Gonzalo-Romeo; Víctor Alastrué-Vera; Dolores Gutiérrez-Blázquez; José M Lou-Bonafonte; Joaquín C Surra; María J Rodríguez-Yoldi; Agustín García-Gil; Antonio Güemes; Jesús Osada
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.